Perianal Crohn's disease is associated with distal colonic disease, stricturing disease behavior, IBD-associated serologies and genetic variation in the JAK-STAT pathway

Inflammatory Bowel Diseases

Volumn 22, Issue 4, 2016, Pages 862-869

  Kaur, Manreet ^a,b   Panikkath, Deepa ^a   Yan, Xiaofei ^a   Liu, Zhenqiu ^a   Berel, Dror ^a   Li, Dalin ^a   Vasiliauskas, Eric A ^a   Ippoliti, Andrew ^a   Dubinsky, Marla ^a   Shih, David Q ^a   Melmed, Gil Y ^a   Haritunians, Talin ^a   Fleshner, Phillip ^a   Targan, Stephan R ^a   McGovern, Dermot P B ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Crohn's disease; genetics; inflammatory bowel disease; perianal Crohn's disease; serology

Indexed keywords

CADHERIN; GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; JANUS KINASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; OUTER MEMBRANE PROTEIN C; PROTEIN; PROTEIN CRTC3; PROTEIN DAPK1; PROTEIN FUT2; PROTEIN JAFZ1; PROTEIN KIF3B; PROTEIN MST1; PROTEIN NDFIP2; PROTEIN NUCB2; PROTEIN PTGER; PROTEIN TRAF3IP2; PROTEIN USH1C; RECEPTOR INTERACTING PROTEIN 140; SCAFFOLD PROTEIN; STAT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN;

ADULT; ANTIBODY BLOOD LEVEL; ANUS FISTULA; ARTICLE; AUTOPHAGY; CASE CONTROL STUDY; CLINICAL FEATURE; COLON DISEASE; CONTROLLED STUDY; CROHN DISEASE; DEMOGRAPHY; ENDOPLASMIC RETICULUM STRESS; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA NODOSUM; EXTRACELLULAR MATRIX; FAMILY HISTORY; FEMALE; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PERIANAL ABSCESS; PERIANAL CROHN DISEASE; POPULATION STRUCTURE; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; SACCHAROMYCES CEREVISIAE; SEROLOGY; SIGNAL TRANSDUCTION; STRICTURING DISEASE; ADOLESCENT; ANUS DISEASE; BLOOD; COLONIC DISEASES; COMPARATIVE STUDY; COMPLICATION; CONSTRICTION, PATHOLOGIC; FOLLOW UP; GENETIC VARIATION; GENETICS; METABOLISM; PATHOLOGY; PHENOTYPE; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANUS DISEASES; CASE-CONTROL STUDIES; COLONIC DISEASES; CONSTRICTION, PATHOLOGIC; CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GENETIC VARIATION; GENOTYPE; HUMANS; INFLAMMATORY BOWEL DISEASES; JANUS KINASES; MALE; PHENOTYPE; PROGNOSIS; STAT3 TRANSCRIPTION FACTOR; YOUNG ADULT;

EID: 84962247996     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000705     Document Type: Article

References (26)

1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46-54.e42; quiz e30.
2. Mahadev S, Young JM, Selby W, et al. Self-reported depressive symptoms and suicidal feelings in perianal Crohn?s disease. Colorectal Dis. 2012;14:331-335.
3. Tang LY, Rawsthorne P, Bernstein CN. Are perineal and luminal fistulas associated in Crohn?s disease? A population-based study. Clin Gastroenterol Hepatol. 2006;4:1130-1134.
4. Eglinton TW, Barclay ML, Gearry RB, et al. The spectrum of perianal Crohn?s disease in a population-based cohort. Dis Colon Rectum. 2012; 55:773-777.
5. Sachar DB, Bodian CA, Goldstein ES, et al. Is perianal Crohn?s disease associated with intestinal fistulization? Am J Gastroenterol. 2005;100: 1547-1549.
6. Karban A, Itay M, Davidovich O, et al. Risk factors for perianal Crohn?s disease: the role of genotype, phenotype, and ethnicity. Am J Gastroenterol. 2007;102:1702-1708.
7. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn?s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875-880.
8. Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn?s disease in a populationbased cohort. Gastroenterology. 2010;139:1147-1155.
9. Cosnes J, Cattan S, Blain A, et al. Long-Term evolution of disease behavior of Crohn?s disease. Inflamm Bowel Dis. 2002;8:244-250.
10. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5A-36A.
11. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn?s disease. Gastroenterology. 2006;130:650-656.
12. Tarrant KM, Barclay ML, Frampton CM, et al. Perianal disease predicts changes in Crohn?s disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol. 2008;103: 3082-3093.
13. Nasir BF, Griffiths L, Nasir A, et al. Perianal disease combined with NOD2 genotype predicts need for IBD-related surgery in Crohn?s disease patients from a population-based cohort. J Clin Gastroenterol. 2013;47: 242-245.
14. Somasundaram R, Nuij VJ, van der Woude CJ, et al. Peripheral neutrophil functions and cell signalling in Crohn?s disease. PLoS One. 2013;8: e84521.
15. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124.
16. McGovern DP, Jones MR, Taylor KD, et al. Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn?s disease. Hum Mol Genet. 2010;19:3468-3476.
17. Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn?s disease-Associated immune responses to auto-And microbial antigens. Gastroenterology. 2002;123:689-699.
18. Haritunians T, Taylor KD, Targan SR, et al. Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis. 2010;16:1830-1840.
19. Howie BN, Donnelly P, Marchini J. (2009) A Flexible and Accurate Genotype Imputation Method for the Next Generation of Genome-Wide Association Studies. PLoS Genet. 5:e1000529. doi: 10.1371/journal.pgen. 1000529.
20. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-Analysis of genomewide association scans. Bioinformatics. 2010;26:2190-2191.
21. Weersma RK, Stokkers PC, van Bodegraven AA, et al. Molecular prediction of disease risk and severity in a large Dutch Crohn?s disease cohort. Gut. 2009;58:388-395.
22. Cepek KL, Shaw SK, Parker CM, et al. Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin. Nature. 1994;372:190-193.
23. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369: 699-710.
24. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn?s disease. N Engl J Med. 2013;369:711-721.
25. Vermeire S, O?Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014; 384:309-318.
26. Sandborn WJ, Ghosh S, Panes J, et al. A phase 2 study of tofacitinib, an oral janus kinase inhibitor, in patients with Crohn?s disease. Clin Gastroenterol Hepatol. 2014;12:1485-1493,e2.